Pyxus International Reports 3.2% Sales Growth in Fiscal Year 2022

Aug.13.2022
Pyxus International Reports 3.2% Sales Growth in Fiscal Year 2022
Pyxus International reports 3.2% growth in sales and revenue for the fiscal year ending June 30, 2022.

Pyxus International is a tobacco company that operates globally.


Pyxus International has reported that its sales and other operating revenues for the fiscal year ending on June 30th, 2022 reached $343.9 million, representing a 3.2% increase from the same period in 2021. However, its net losses increased by 27.8%, amounting to $14.7 million, primarily due to a decrease in tax benefits by $7.6 million. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 17.1% to $17.3 million.


In a statement, Pyxus CEO Pieter Sikkel said, "As expected, our first quarter results were in line with the previous fiscal year. Demand from Asia increased and shipping times have become more normalized, but this was partially offset by longer shipping times from Africa and South America.


As of June 30th, 2022, our inventory has increased by $126 million compared to the previous year. This is primarily due to rising prices and processing costs for new crop green tobacco in South America, as well as the accelerated purchase activity for new crops in certain key markets. Additionally, over 90% our processed tobacco inventory is still allocated to specific customers.


The overall increase in inventory and the processing tobacco inventory levels we committed to have enabled us to meet current demand, and we anticipate strong shipment volumes for subsequent quarters in fiscal year 2023, consistent with historical trends. Despite higher green tobacco prices and processing costs in South America, we have effectively managed working capital to achieve our procurement objectives for the current crop cycle.


Due to unfavorable weather patterns from the La Niña season, crop yields in certain markets in Africa, Asia, and South America have fallen below expectations, exacerbating supply shortages. We are maintaining transparent dialogue with our clients regarding the impact of La Niña and inflation on our business. To address these and other market dynamics, we have accelerated purchasing activities in key markets and continue to invest in research trials, local projects, and additional training for our global agronomy team to further support our efforts to maximize grower efficiency and yields in unpredictable weather patterns.


We continue to anticipate that sales for the fiscal year 2023 will fall between $1.75 billion and $1.95 billion, while adjusted EBITDA will fall between $130 million and $160 million. Looking ahead, we are committed to restoring crop size and ensuring that the quantities in the upcoming years align with customers' expectations as we strive to provide value to stakeholders and work together towards a better world.


This article is compiled from third-party information and is intended for industry professionals to share and learn.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of the article content. The translation of this article is solely for industry communication and research purposes.


Due to limitations in translation ability, the article may not express the original text accurately. Please refer to the original text for accuracy.


2FIRSTS aligns fully with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements or positions.


Copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Thai Health Authorities: Nicotine Pouches Classified as Tobacco; Sales Must Comply with 2017 Act
Thai Health Authorities: Nicotine Pouches Classified as Tobacco; Sales Must Comply with 2017 Act
Thailand’s Disease Control Department has warned that nicotine pouches (“Snus”) are classified as tobacco products and must comply with the Tobacco Products Control Act B.E. 2560 (2017). Officials said they have received complaints about sales and promotional activities, and stressed that these products must not be displayed or promoted at points of sale.
Feb.02 by 2FIRSTS.ai
China’s E-Cigarette Exports USD 1.096 billion in November, UK and South Korea Offset U.S. Decline
China’s E-Cigarette Exports USD 1.096 billion in November, UK and South Korea Offset U.S. Decline
China’s e-cigarette exports edged lower in November 2025, totaling USD 1.096 billion, down 0.2% month-on-month, as a decline in shipments to the United States was partially offset by stronger demand from the United Kingdom, Germany and South Korea, according to data released by the General Administration of Customs of China.
Dec.22 by 2FIRSTS.ai
KT&G says lil reached about US$2.924 billion in cumulative sales and is expanding overseas
KT&G says lil reached about US$2.924 billion in cumulative sales and is expanding overseas
KT&G said its HNB brand lil has grown since launch, reporting KRW 7.8 billion (about US$5.304 million) in sales in 2017 and about KRW 4.3 trillion (about US$2.924 billion) in cumulative sales by last year’s third quarter, with KRW 5 trillion (about US$3.400 billion) described as within reach. KT&G said lil has entered more than 30 countries and supplies some products abroad via a partnership with PMI.
Jan.13 by 2FIRSTS.ai
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.
Regulations
Dec.20
South Korea to regulate synthetic-nicotine e-liquids as tobacco from April 24
South Korea to regulate synthetic-nicotine e-liquids as tobacco from April 24
South Korea’s Health Ministry says amendments to the Tobacco Business Act will take effect on April 24, bringing synthetic-nicotine e-liquid vapes under the legal definition of tobacco. The shift extends cigarette-style rules to these products, including mandatory graphic warnings, sharply limited advertising channels, stricter vending-machine placement requirements, and a ban on use in smoke-free areas, with enforcement checks slated from late April.
Feb.03 by 2FIRSTS.ai
Report Says Teen e-cigarette use on the rise, with majority of sales coming from disposable products
Report Says Teen e-cigarette use on the rise, with majority of sales coming from disposable products
Monitoring a Changing Tobacco Product Market in the United States is the second annual review from the Monitoring Tobacco Product Use project, analyzing retail scanner data from January 2019 to December 2024 and TEEN+ survey data.
Jan.07 by 2FIRSTS.ai